Portée, part et taille du marché du développement de lignées cellulaires d'ici 2031
Cell Line Development Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 6.86 Billion |
| Market Size by 2031 | US$ 18.62 Billion |
| Global CAGR (2023 - 2031) | 13.3% |
| Historical Data | 2021-2022 |
| Forecast period | 2023-2031 |
| Segments Covered | By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
Market Players Density: Understanding Its Impact on Business Dynamics
The Cell Line Development Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Cell Line Development Market are:
- Thermo Fisher Scientific Inc
- Merck KGaA
- Selexis SA (JSR Corporation)
- BioFactura, Inc
- Corning Incorporated
- Sartorius AG
Disclaimer
: The companies listed above are not ranked in any particular order.
- Get the Cell Line Development Market top key players overview
Cell Line Development Market News and Recent Developments
The cell line development market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for cell line development and strategies:
- Abzena announced on Jan. 16, 2023 the launch of AbZelect and AbZelectPRO, its new cell line development (CLD) platforms, designed to speed up the generation of production cell lines for the manufacture of antibodies and recombinant proteins. The platforms are intended to enable the rapid progress of complex biologic drug programs towards clinical trials and investigational new drug (IND) application filing. (Source: Abzena Company Name, Newletter, 2023)
- Lonza announced the launch of its new GS Effex cell line for the development of therapeutic antibodies with enhanced potency. The GS Effex cell line was developed to meet pressing market needs originating from the shift towards more sophisticated therapeutic antibodies. Derived from Lonza’s leading GS Xceed cell line, GS Effex fits effectively into Lonza platforms. Combined with good cell growth and the ability to produce therapeutic antibodies with increased potency, the new cell line provides a solution for therapeutic development from discovery stage research through to commercial manufacturing. (Source: Lonza Company Name, Press Release, 2023)
Cell Line Development Market Report Coverage and Deliverables
The “Cell Line Development Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Market dynamics such as drivers, restraints, and key opportunities
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Analyse du marché mondial et régional couvrant les principales tendances du marché, les principaux acteurs, les réglementations et les développements récents du marché
- Analyse du paysage industriel et de la concurrence couvrant la concentration du marché, l'analyse de la carte thermique, les principaux acteurs et les développements récents
- Profils d'entreprise détaillés
Get Free Sample For